Hunziker EB, Quinn TM, Hauselmann HJ
So I wrote a little thing for @MolMetab sciencedirect.com/science/articl As we now appreciate, GLP-1 can target multiple brain regions and neuronal populations to reduce food intake, and the clinical results are increasingly impressive #obesity The ongoing SELECT trial will be pivotal for the field sciencedirect.com/science/articl From very modest weight loss with exenatide twice daily, the GLP-1 field has learned, by titration, dose escalation, higher Cmax, and better molecules, to achieve clinically meaningful #weightloss #T2D #obesity More progress to come #obesity described here sciencedirect.com/science/articl Beyond semaglutide and tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and make projections out to 52 weeks thelancet.com/journals/lance Join the conversation
Knockdown of SLC1A5_var resulted in reduced GSH and increased ROS levels, while overexpression of SLC1A5_var promoted PC cell and tumor growth [36]
By encasing glutathione in tiny lipid bubbles called liposomes, this advanced formula helps deliver the antioxidant through your gut and directly into your cells without being broken down along the way
Both conditions respond to hormonal changes during perimenopause and may cause symptoms that weren't present before
